Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War

Core Viewpoint - Hims & Hers' stock has plummeted to new 52-week lows due to significant regulatory and legal challenges surrounding its recent product launch [1] Regulatory Response - Hims & Hers attempted to launch a compounded oral semaglutide pill, a copy of Novo Nordisk's oral Wegovy, but faced immediate regulatory backlash, leading to the company halting the product just 48 hours after its introduction [2] Legal Challenges - Novo Nordisk has initiated a patent infringement lawsuit against Hims & Hers, escalating the legal disputes surrounding the company's new product line [3] Market Reaction - The uncertainty regarding Hims & Hers' ability to sell its new product has led to a drastic sell-off, with the stock experiencing over four times its average trading volume before noon on Monday. The stock price fell by 20.10%, reaching $18.39 at the time of publication [4]